Stocks to buy: 5 short-term trading ideas by experts for 22 December 2022
On the downside, the area between 18,133 and 18,080 represents a significant demand zone. As long as Nifty trades above 18,080, the general bullish texture will hold, but below 18,080, we can anticipate a short-term trend reversal,” Santosh Meena, Head of Research, Swastika Investmart Ltd., said.
Diagnostic players rally up to 6% amid China covid surge
“The near-term market construct is not favourable for equities. The rising Covid cases in the US, Korea, Brazil, and China is an area of concern. The situation is dire in China. This might impact market sentiments,” V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services said.
Saurabh Mukherjea PMS fund nearly doubles investor wealth in 4 years
In the highly concentrated long-term portfolio, almost all stocks have compounded their share prices at 15-30% annually demonstrating that stock selection contributed significantly to portfolio returns, the PMS fund said.
ETMarkets Smart Talk: IT & PSU banks could turn out to be the Dark Horse of Samvat 2079: Rahul Shah
"The IT sector has been a pleasant surprise as far as the results are concerned. Top-line growth across most major companies has come in better than expected whereas attrition pressures have also eased, thus keeping both the growth as well as margins healthy. This, combined with attractive valuations, makes the sector a good bet from a 2-3 year perspective."
Trade Spotlight | What should you do with India Cements, Dr Lal PathLabs, Glenmark Pharma on Thursday?
Dr Lal PathLabs shares gained 1.7 percent to Rs 2,694.35, continuing uptrend for the seventh consecutive session. It has seen formation of bullish candle on the daily charts with higher high higher low formation for seven straight sessions, and has given a breakout of downward sloping resistance trend line adjoining April 8 and August 26.
Hot Stocks: Global brokerages on HDFC Life, Dr Lal PathLabs and Emami
The global investment bank expects Emami's growth to recover from H2FY23 after a very high base. Margin pressures will persist in the near term, it said. It marginally lowered FY23/24/25 EPS by 2-3 per cent. Emami trades at 26x FY24 earnings ~40 per cent discount to the peers, said the note.
Stocks in the news: Dreamfolks Services, Dixon Tech, Cipla, Adani Ports and Reliance Power
The company is pivoting from a prescription manufacturing service to an original device manufacturer (ODM) for smart TVs, having acquired sub-licensing rights for Google TV and Android TV from Google. The rights, announced by Dixon on Monday, will enable the firm to both design and manufacture smart LED TVs for third-party brands.
Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation pressure is high.
Dr Lal PathLabs pulls up its socks as competition mounts
Gurgaon-headquartered Dr Lal PathLabs and other diagnostic chains are feeling the heat due to the big drop in demand for Covid-19 testing, competition intensifying with the entry of e-pharmacies, web aggregators and pharma companies into diagnostics, resulting in a price war at a time when inflation pressure is high.
#LALPATHLAB Seems to be moving out of downtrend. A clear pin bar formation is visible on daily chart. With a stop loss below 2270 , a positional long can be initiated.
The relative strength is recovering, a break out in the same will increase the momentum of the uptrend. See th......read more
Hot Stocks | Here is why you should bet on Dr Lal PathLabs and TCS for short term
Dr Lal PathLabs witnessed an ascending triangle pattern breakout on July 29 which was placed above Rs 2,250 levels in the daily time frame. After breakout, prices are showing a gradual upside movement in a small steep formation.
Dr Lal PathLabs Q1 Results: Net profit dips 57% to Rs 58 crore
The company had reported a net profit of Rs 134 crore in the April-June period of the last fiscal.Revenue from operations declined to Rs 503 crore in the period under review from Rs 607 crore a year ago, Dr Lal PathLabs said in a regulatory filing.
Hurun power-list: Roshni Nadar Malhotra of HCL wealthiest woman with Rs 84K cr net worth, Nykaa's Falguni Nayar beats Biocon boss for richest self-made billionaire
Indra Nooyi is the richest professional manager with Rs 5K cr wealth.
FMCG spices it up, pharma takes a shot at diagnostics
Ahmedabad-based drug major Torrent Pharma is reportedly set to foray into the diagnostics business, although a formal announcement is awaited. Last year, its Mumbai-based peer Lupin made an organic foray into the ₹70,000-crore sector. Mankind Pharma and Reliance Life Sciences are other large players that have entered the sector.
Indian equity benchmark indices settled 1 percent lower for the week ended July 15 amid volatility, weak GDP data and rising global inflation, which fueled the fears of a further rate hike by central banks across the world......read more
More than 800 active integrations on Ayushman Bharat Digital Mission: NHA
As per the ABDM website, more than 22.33 crore health IDs have been created, 62,182 health facilities registered, 14,840 doctors registered, more than 5.43 lakh downloads of the Health Records App has been done, 867 integrators are active out of which 40 of them have been successful.
NOTE : I AM NOT SEBI REGISTERED . ITS ONLY MY PERSONAL VIEW AND ONLY FOR EDUCATION PURPOSE NOT FOR TRADE........AND ALL TRADES ARE FOR INTRADAY ONLY........